7 Major Japan Drug Makers Net Two-Digit Growth in Combined H1 Sales on Flagship Brands, Upfront Income

Seven leading Japanese drug makers chalked up double-digit growth in their combined sales in the first half of FY2021 as their major global products performed strongly, coupled with licensing income, to more than offset their sluggish earnings in the home...read more